Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD - Synopsis below extracted from the video transcript.
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids MD - Synopsis below extracted from the video transcript.
Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study
Allogeneic Hematopoietic Cell Transplantation: Relapsed or Refractory AML Phase 3 ASAP Trial Johannes Schetelig - Synopsis below extracted from the video transcript.
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD - Synopsis below extracted from the video transcript.
Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD - Synopsis below extracted from the video transcript.
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD - Synopsis below extracted from the video transcript.
Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD - Synopsis below extracted from the video transcript.
Urothelial Cancer: What’s New in 2023? [Slides] Targeted and Novel Therapies Nataliya Mar MD - Synopsis below extracted from the video transcript.
How effective is mosunetuzumab in treating lymphoma? - [Slides] Elizabeth Budde, MD 2023 reviews new therapies - Synopsis below extracted from the video transcript.